ICON Selected by the Biomarkers Consortium of the FNIH to Support Study Evaluating Variability in Insulin Secretory Parameters
ICON's metabolic research team will support the clinical execution of this project, including subject recruitment and testing in ICON's Clinical Pharmacology Unit, located in San Antonio, Texas.
The Biomarkers Consortium study aims to develop biomarkers that predict long-term beta cell function, particularly in response to an intervention or a new therapy for diabetes. Currently there is no accepted gold standard testing regimen for estimating beta cell function and many accepted regimens are technically complex, making them unsuitable for large, multi-center clinical studies. The study is one of a series
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025